Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 9.50M | 9.23M | 8.59M | 7.93M | 7.22M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 14.82M | 13.74M | 12.51M | 11.21M | 10.08M |
Operating Income | -14.82M | -13.74M | -12.51M | -11.21M | -10.08M |
Income Before Tax | -7.67M | -11.16M | -17.78M | -19.47M | -22.53M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -7.67 | -11.16 | -17.78 | -19.47 | -22.53 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -7.67M | -11.16M | -17.78M | -19.47M | -22.53M |
EBIT | -14.82M | -13.74M | -12.51M | -11.21M | -10.08M |
EBITDA | -14.64M | -13.58M | -12.37M | -11.09M | -9.99M |
EPS Basic | -0.21 | -0.35 | -0.60 | -0.67 | -0.77 |
Normalized Basic EPS | -0.13 | -0.22 | -0.38 | -0.42 | -0.48 |
EPS Diluted | -0.21 | -0.35 | -0.60 | -0.67 | -0.77 |
Normalized Diluted EPS | -0.13 | -0.22 | -0.38 | -0.42 | -0.48 |
Average Basic Shares Outstanding | 137.04M | 131.50M | 125.60M | 120.31M | 115.83M |
Average Diluted Shares Outstanding | 137.04M | 131.50M | 125.60M | 120.31M | 115.83M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |